SEATTLE, Feb. 05, 2018 (GLOBE NEWSWIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and
molecular diagnostic products, today announced the publication of a landmark
study in which Danish researchers used the Prosigna ® Breast Cancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to
nationwide guidelines between 2000 and 2003.